Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Biotech·Estuary Biotherapeutics

Estuary launches with $103M to take kidney-delivered gene therapies for ADPKD into the clinic

RA Capital led a $93 million Series A for the startup, which is built on Yale research and plans to start human testing of its first polycystic kidney disease program in 2027.

Charted Staff3 min read
From a company announcement published Oct. 16, 2026
Cell-culture flasks, dishes and plates inside a laboratory incubator.
Cell-culture flasks, dishes and plates inside a laboratory incubator. File photo.Shinryuu / Wikimedia Commons (public domain)
Amount
$93M
Type
Series A
Company
Estuary Biotherapeutics
Lead investor
RA Capital Management
Sector
Biotech
Announced
Oct. 16, 2026

Gene therapy for kidney disease has a delivery problem, Estuary Biotherapeutics says, and the startup is betting $103 million that it can solve it by delivering the treatment directly to the kidney rather than through the bloodstream.

Estuary said Oct. 16 that it launched with $103 million in committed financing in all, including a $93 million Series A led by RA Capital Management. The company lists offices in Menlo Park, Calif., and Newton, Mass., and is developing gene therapies for autosomal dominant polycystic kidney disease, or ADPKD.

Why it matters: Estuary is going after the genetic cause of a common inherited kidney disease for which, according to the company, there is one FDA-approved therapy, tolvaptan, sold as Jynarque. It says its treatments could potentially be given once. Neither program has yet entered human testing; the first is scheduled to start in 2027.

Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office connected to a person living with ADPKD joined the Series A. 4BIO Capital and GV, which co-led Estuary's earlier $10 million seed round, also invested. Emily Minkow, a managing director at RA Capital, and Owen Smith, a partner at 4BIO Capital, sit on the board.

Two programs, two genes

Estuary said the money will take EST-201 and EST-101, its two lead programs, through clinical proof of concept and pay for further work on what it calls its kidney-targeting platform.

Both use an adeno-associated virus, or AAV, to deliver genetic material. According to the company, EST-201 delivers a full-length PKD2 gene and is expected to reach the clinic in 2027 in ADPKD patients with PKD2 mutations. EST-101 uses the same vector to deliver a functional piece of the polycystin-1 protein and is slated for the clinic in 2028 in patients with PKD1 mutations.

The company said the therapies are designed to be given locally to the kidney, potentially once, instead of systemically. It said keeping the treatment confined to the kidney is meant to sidestep many of the problems that have complicated AAV gene therapies given systemically. Estuary contrasted its approach with other ADPKD therapies that, it said, act on pathways downstream of the disease's genetic cause.

Wayne Sackett, Estuary's co-founder and chief executive, said the team "is moving with urgency to bring these important medicines into the clinic."

The science and the patients

The programs build on mouse studies by Estuary's scientific co-founders, Stefan Somlo and Michael Caplan of the Yale School of Medicine, the company said. According to Estuary, Somlo showed that restoring polycystin in mouse kidneys with established cysts could reverse the disease's structural and functional hallmarks, and Caplan showed that a compact region of polycystin-1 was sufficient to suppress the disease in mice.

Estuary says no inherited kidney disease is more common than ADPKD, which it says affects over 8 million people around the world and is the fourth most common reason for kidney replacement therapy globally. In more than 90% of patients, it said, the disease is caused by mutations in PKD1 or PKD2, and the cysts that form can eventually lead to kidney failure requiring dialysis and transplantation.

The company estimates that 10,000 to 15,000 U.S. patients have rapidly progressing PKD2-linked disease and 100,000 to 140,000 have rapidly progressing PKD1-linked disease. It says those are the patients EST-201 and EST-101, respectively, would first be aimed at.

Jeremy Duffield is chief scientific officer and Uptal Patel is chief medical officer. Jake Bauer is the independent board chair.

What to watch

The first test is EST-201's clinic entry, planned for 2027. Estuary has not said where its first trial will run, how the kidney-directed delivery will be performed in patients or how many people it will enroll. EST-101 would follow in 2028.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Biotech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.